Methotrexate in acute persistent humoral rejection: an option for graft rescue

Fernando Bacal; Gustavo L Sodré; Daniela A Fernandes; Vera D Aiello; Noedir Stolf; Edimar Bocchi; Giovanni Bellotti

doi:10.1016/s0003-4975(03)00143-7

Methotrexate in acute persistent humoral rejection: an option for graft rescue

Ann Thorac Surg. 2003 Aug;76(2):607-10. doi: 10.1016/s0003-4975(03)00143-7.

Authors

Fernando Bacal¹, Gustavo L Sodré, Daniela A Fernandes, Vera D Aiello, Noedir Stolf, Edimar Bocchi, Giovanni Bellotti

Affiliation

¹ Heart Failure Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil. fbacal@uol.com.br

PMID: 12902116
DOI: 10.1016/s0003-4975(03)00143-7

Abstract

Humoral response emerges as an important component in acute graft rejection and a new challenge to clinicians in posttransplant care. Management of recurrent episodes and persistent activation of the humoral component of the immune system, despite the usual therapeutic approach to rejection, remains unknown. This article describes the successful use of methotrexate as an option for rescuing a graft in this worrisome situation.

Publication types

Case Reports

MeSH terms

Acute Disease
Adult
Antibody Formation / physiology
Cardiomyopathy, Dilated / diagnosis
Cardiomyopathy, Dilated / surgery*
Dose-Response Relationship, Drug
Drug Administration Schedule
Graft Rejection / prevention & control*
Graft Survival
Heart Transplantation / adverse effects
Heart Transplantation / immunology*
Heart Transplantation / methods
Humans
Male
Methotrexate / administration & dosage*
Prognosis
Transplantation Immunology
Treatment Outcome

Substances

Methotrexate